PAVM Stock Overview
PAVmed Inc. operates as a medical device company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
PAVmed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.95 |
| 52 Week High | US$9.36 |
| 52 Week Low | US$1.60 |
| Beta | 0.83 |
| 1 Month Change | -4.88% |
| 3 Month Change | -28.31% |
| 1 Year Change | -76.79% |
| 3 Year Change | -96.98% |
| 5 Year Change | -89.43% |
| Change since IPO | -99.00% |
Recent News & Updates
Recent updates
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?
Jan 29
Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?
Aug 17PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
Aug 16PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress
Jul 05Start Accumulating PAVmed
Dec 24We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth
Sep 02PAVmed: Long Term Investment Case Remains Despite Weak Q2
Aug 23PAVmed: A True Game-Changer For Medical Device Innovation
Jun 14PAVmed forms digital health company, Veris Health
Jun 02PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device
May 26PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans
May 19PAVmed drops 14% on launch of $13.4M direct offering
Jan 06PAVmed closes additional direct offering of common stock
Dec 22Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?
Dec 16PAVmed offers stock for $8.9M
Dec 11PAVmed EPS beats by $0.02
Nov 17There Is Progress At PAVmed, But More Patience Is Required
Oct 30Shareholder Returns
| PAVM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.5% | -4.1% | -3.7% |
| 1Y | -76.8% | -2.2% | 20.5% |
Return vs Industry: PAVM underperformed the US Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: PAVM underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| PAVM volatility | |
|---|---|
| PAVM Average Weekly Movement | 20.7% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PAVM's share price has been volatile over the past 3 months.
Volatility Over Time: PAVM's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 107 | Lishan Aklog | www.pavmed.com |
PAVmed Inc. operates as a medical device company in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett’s Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform.
PAVmed Inc. Fundamentals Summary
| PAVM fundamental statistics | |
|---|---|
| Market cap | US$17.89m |
| Earnings (TTM) | -US$66.27m |
| Revenue (TTM) | US$2.45m |
7.3x
P/S Ratio-0.3x
P/E RatioIs PAVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAVM income statement (TTM) | |
|---|---|
| Revenue | US$2.45m |
| Cost of Revenue | US$6.42m |
| Gross Profit | -US$3.97m |
| Other Expenses | US$62.30m |
| Earnings | -US$66.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.22 |
| Gross Margin | -161.83% |
| Net Profit Margin | -2,702.69% |
| Debt/Equity Ratio | -184.0% |
How did PAVM perform over the long term?
See historical performance and comparison